Screener / SEC EDGAR /CIK 0001609550 /10-K filed Feb 13, 2026, compared with Feb 10, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Health care · Medical Instruments

Inspire Medical Systems, Inc. INSP

Compare with peers Embed
FY2025 at a glance

Sales up 13.6%, free cash flow down to $78.5M

XBRL, from each 10-K
RevenueStatements
$912.0M from $802.8M in FY2024
FY2016FY2025
Net incomeStatements
$145.4M from $53.5M in FY2024
FY2016FY2025
Free cash flowStatements
$78.5M from $91.1M in FY2024
FY2016FY2025
EPS (diluted)Statements
$4.89 from $1.75 in FY2024
FY2016FY2025
Operating marginStatements
5.6% from 4.5% in FY2024
FY2016FY2025

The latest figures

Price and key numbers

From EDGAR
All key numbers (40)
EPS (ttm)
3.35
Sales (ttm)
880.9M
Net income (ttm)
100.7M
Sales growth
+13.6%
EPS growth
+179%
Sales Q/Q
-7.9%
Free cash flow
97.9M
Gross margin
86.2%
Oper. margin
1.8%
Net margin
11.4%
FCF margin
11.1%
R&D / sales
11.3%
Dividend
-
Debt/Eq
-
Curr. ratio
6.45
Cash
190.8M
Op. cash flow (ttm)
135.0M
EBITDA
64.9M
EBITDA margin
7.1%
Quick ratio
4.96
Interest cover
371.93
ROIC
13.6%
FCF after stock pay
-51.8M
Oper. margin low 5y
-17.1%
Tax rate
-121.4%
Stock pay / sales
14.3%
Shares out.
29.0M
Shares Y/Y
-2.6%
Book / share
28.55
Cash / share
6.59
Sales / share
30.41
Asset turnover
0.92
Inventory turns
0.92
Days sales out.
48
Sales 3Y CAGR
+30.8%
Sales 5Y CAGR
+51.2%
Employees
1,333
Sales / employee
661K

Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.

Revenue and net income, FY2016 to FY2025

Each fiscal year from its own 10-K · XBRL

Revenue 912.0M +56.3% a year Net income 145.4M
FY2016 revenue 16.4M · Revenues, 0001609550-19-000013 FY2016 net income -18.5M · NetIncomeLoss, 0001609550-19-000013 16.4M FY2016 FY2017 revenue 28.6M · Revenues, 0001609550-20-000011 FY2017 net income -17.5M · NetIncomeLoss, 0001609550-20-000011 28.6M FY2017 FY2018 revenue 50.6M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001609550-21-000010 FY2018 net income -21.8M · NetIncomeLoss, 0001609550-21-000010 50.6M FY2018 FY2019 revenue 82.0M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001609550-22-000014 FY2019 net income -33.2M · NetIncomeLoss, 0001609550-22-000014 82.0M FY2019 FY2020 revenue 115.4M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001609550-23-000024 FY2020 net income -57.2M · NetIncomeLoss, 0001609550-23-000024 115.4M FY2020 FY2021 revenue 233.4M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001609550-24-000016 FY2021 net income -42.0M · NetIncomeLoss, 0001609550-24-000016 233.4M FY2021 FY2022 revenue 407.9M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001609550-25-000011 FY2022 net income -44.9M · NetIncomeLoss, 0001609550-25-000011 407.9M FY2022 FY2023 revenue 624.8M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001609550-26-000016 FY2023 net income -21.2M · NetIncomeLoss, 0001609550-26-000016 624.8M FY2023 FY2024 revenue 802.8M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001609550-26-000016 FY2024 net income 53.5M · NetIncomeLoss, 0001609550-26-000016 802.8M FY2024 FY2025 revenue 912.0M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001609550-26-000016 FY2025 net income 145.4M · NetIncomeLoss, 0001609550-26-000016 912.0M FY2025

From XBRL in each 10-K. Hover a bar for the line item and filing. "A year" is the steady yearly growth from FY2016 to FY2025 (9 years).

Growth per share, FY2016 to FY2025

Earnings, book value and free cash flow for each diluted share · 10-K XBRL, every year linked to its filing

Average yearly growth
Book value per share +28.3% a year FY2019 $5.87 to FY2025 $26.25, 6 years
Fiscal year toEPS (diluted)Book value / shareFree cash flow / share
Dec 31, 2025 $4.89$26.25$2.64
Dec 31, 2024 $1.75$22.58$2.98
Dec 31, 2023 -$0.72$19.54$0.03
Dec 31, 2022 -$1.60$17.67$0.09
Dec 31, 2021 -$1.54$8.40-$0.91
Dec 31, 2020 -$2.19$8.81-$2.13
Dec 31, 2019 -$1.40$5.87-$1.49
Dec 31, 2018 ---
Dec 31, 2017 ---
Dec 31, 2016 ---

Per share means per diluted weighted-average share of the same fiscal year (the count under diluted EPS, put on today's share count after a split). Book value is shareholders' equity at the year end, including any preferred stock; free cash flow is operating cash flow less capital spending. Each tile's rate is the steady yearly growth from the first to the last year it names: the window starts at the oldest year, up to ten years back, with a value above zero.

What the balance sheet holds, per share

Net current asset value and tangible book value, FY2025 · 10-K XBRL, no share price used

Net current asset value, FY2025, in dollars
  • + Current assets $583.7M
  • − All liabilities $126.2M
  • = Net current asset value $457.5M
Per share, year by year
Tangible book value, FY2025, in dollars
  • + Shareholders' equity $781.2M
  • = Tangible book value $781.2M
Per share, year by year

Net current asset value is current assets minus all liabilities (the long-term ones too), so it is what would be left from the short-term assets after everything owed is paid; it is blank for a bank, which reports no current assets. Tangible book value is shareholders' equity minus goodwill and other intangible assets; equity includes any preferred stock. Both are divided by the diluted weighted-average share count of the same fiscal year. Red bars are amounts taken off, or a negative result.

INSP against Health care peers

Among the 162 companies, the better end on the right. The band holds the middle half; the line is the median.

Ten years, side by side
Sales growth
+4.8%+20.2%
+13.6%59th of 155 · median +10.5%
Net margin
-4.1%15.3%
11.4%57th of 154 · median 6.8%
Return on equity
-5.2%18.5%
12.2%60th of 144 · median 9.2%
Free cash flow margin
2.3%19.2%
11.1%66th of 145 · median 10.0%
INSP and the 5 peers closest in revenue
CompanyRevenue (ttm)Sales growthFYGross marginttmNet marginttmROEttmFCF marginttmDebt / equitylatest
INSP Inspire Medical Systems, Inc.$880.9M +13.6%86.2%11.4%12.2%11.1%-
WRBY Warby Parker Inc.$934.7M +13.0%54.7%0.8%1.9%2.3%-
TGTX TG Therapeutics, Inc.$897.8M +87.3%82.7%11.8%18.5%9.5%1.30
AXSM Axsome Therapeutics, Inc.$865.3M +65.5%--18.2%-149.2%-9.5%1.78
SUPN Supernus, Inc.$865.1M +8.6%87.6%-5.1%-4.1%10.1%-
IRTC iRhythm Holdings, Inc.$854.0M +26.2%72.3%-4.5%-21.8%0.9%-
All 162 companies in the group

Where each dollar goes

Revenue through the costs to the net profit, from the 10-K income statement and revenue by region

From $802.8M of sales to $53.5M of profit FY2024

  • United States $771.0M
  • All other countries $31.8M
Revenue to Gross profit: $679.8MRevenue to Cost of revenue: $123.0MGross profit to Operating profit: $36.1MGross profit to Operating expenses: $643.7MOperating profit to Net profit: $31.1MOperating profit to Tax: $4.9MOther income to Net profit: $22.4MOperating expenses to R&D: $114.1MOperating expenses to SG&A: $529.6M Revenue: $802.8M REVENUE $802.8M +28% Y/Y Gross profit: $679.8M · 85% margin GROSS PROFIT $679.8M 85% margin · +29% Y/Y Cost of revenue: $123.0M · 15% of revenue COST OF REVENUE $123.0M 15% of revenue Operating profit: $36.1M · 4% margin OPERATING PROFIT $36.1M 4% margin Other income: $22.4M · 3% of revenue OTHER INCOME $22.4M 3% of revenue Operating expenses: $643.7M · 80% of revenue OPERATING EXPENSES $643.7M 80% of revenue Net profit: $53.5M · 7% margin NET PROFIT $53.5M 7% margin Tax: $4.9M · 1% of revenue TAX $4.9M 1% of revenue R&D: $114.1M · 14% of revenue R&D $114.1M 14% of revenue SG&A: $529.6M · 66% of revenue SG&A $529.6M 66% of revenue

From $912.0M of sales to $145.4M of profit FY2025

  • United States $872.1M
  • All other countries $39.9M
Revenue to Gross profit: $778.8MRevenue to Cost of revenue: $133.2MGross profit to Operating profit: $51.0MGross profit to Operating expenses: $727.8MOperating profit to Net profit: $51.0MOther income to Net profit: $94.5MOperating expenses to R&D: $103.2MOperating expenses to SG&A: $624.6M Revenue: $912.0M REVENUE $912.0M +14% Y/Y Gross profit: $778.8M · 85% margin GROSS PROFIT $778.8M 85% margin · +15% Y/Y Cost of revenue: $133.2M · 15% of revenue COST OF REVENUE $133.2M 15% of revenue Operating profit: $51.0M · 6% margin OPERATING PROFIT $51.0M 6% margin · +41% Y/Y Other income: $94.5M · 10% of revenue OTHER INCOME $94.5M 10% of revenue Operating expenses: $727.8M · 80% of revenue OPERATING EXPENSES $727.8M 80% of revenue Net profit: $145.4M · 16% margin NET PROFIT $145.4M 16% margin · +172% Y/Y R&D: $103.2M · 11% of revenue R&D $103.2M 11% of revenue SG&A: $624.6M · 68% of revenue SG&A $624.6M 68% of revenue

Where each $100 of sales went

FY2024
FY2025
  • Cost of revenue
  • Costs, tax, other
  • Net profit

Band widths are the money. Gross profit is revenue less cost of revenue; operating expenses are gross profit less operating profit; R&D is from the income statement and the rest of the operating expenses is everything else; tax includes interest and other items when they are small. Y/Y is the change from the fiscal year before. Revenue by part only for the years in the last two 10-Ks' segment tables. The full income statement

Where the return on equity comes from

DuPont: net margin × asset turnover × leverage, FY2025 against FY2020 · 10-K XBRL, year-end balances

Return on equity 18.6% FY2020: -24.9% net income ÷ equity
Net margin 15.9% FY2020: -49.6% profit per $ of sales: 145.4M ÷ 912.0M
Asset turnover 1.01× FY2020: 0.41× sales per $ of assets: 912.0M ÷ 907.3M
Leverage 1.16× FY2020: 1.22× assets per $ of equity: 907.3M ÷ 781.2M

The three parts multiply to the return on equity. A higher return from leverage alone means more debt or less equity (buybacks shrink equity), not a better business. Year-end balances as filed, not averages, so each number is one line of one 10-K; hover a box for its XBRL tags.

Profitability

  • Net margin above the peer median
    11.4% vs 6.8%
  • Gross margin up over 5 years
    84.7% → 85.4%
  • Return on equity below 15%
    12.2%
  • A profit in 2 of 10 years
Net margin, FY2016 to FY2025: -112.8% to 15.9%

Balance sheet

  • Interest covered more than 5 times
    Operating income is over 100× interest expense
  • Current assets cover current liabilities
    Current ratio 6.45
Debt / equity at each year end, FY2016 to FY2025: 12.40 to 0.00

Cash and shareholders

  • Free cash flow positive in 4 of 10 years
    $78.5M last year
  • Share count up over 5 years
    +14.1%
  • Cash from operations below net income
    $117.0M vs $145.4M
Free cash flow, FY2016 to FY2025: -18.3M to 78.5M

Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.

Income statement, balance sheet and cash flow

Statements · XBRL, each 10-K and 10-Q

From EDGAR

INSP's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year, the last 10. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.

Revenue912.0M
FY2016: 16.4MFY2017: 28.6MFY2018: 50.6MFY2019: 82.0MFY2020: 115.4MFY2021: 233.4MFY2022: 407.9MFY2023: 624.8MFY2024: 802.8MFY2025: 912.0M FY2017FY2019FY2021FY2023FY2025
Net income145.4M
FY2016: -18.5MFY2017: -17.5MFY2018: -21.8MFY2019: -33.2MFY2020: -57.2MFY2021: -42.0MFY2022: -44.9MFY2023: -21.2MFY2024: 53.5MFY2025: 145.4M FY2017FY2019FY2021FY2023FY2025
Free cash flow78.5M
FY2016: -18.3MFY2017: -16.2MFY2018: -18.9MFY2019: -35.6MFY2020: -55.5MFY2021: -24.8MFY2022: 2.5MFY2023: 1.0MFY2024: 91.1MFY2025: 78.5M FY2017FY2019FY2021FY2023FY2025
Free cash flow after stock pay-51.8M
FY2016: -18.5MFY2017: -16.4MFY2018: -20.2MFY2019: -41.8MFY2020: -68.3MFY2021: -51.0MFY2022: -49.5MFY2023: -81.4MFY2024: -24.9MFY2025: -51.8M FY2017FY2019FY2021FY2023FY2025
EPS (diluted)4.89
FY2016: -16.90FY2017: -14.88FY2018: -1.50FY2019: -1.40FY2020: -2.19FY2021: -1.54FY2022: -1.60FY2023: -0.72FY2024: 1.75FY2025: 4.89 FY2017FY2019FY2021FY2023FY2025
Diluted shares29.8M
FY2016: -FY2017: -FY2018: -FY2019: 23.8MFY2020: 26.1MFY2021: 27.3MFY2022: 28.1MFY2023: 29.3MFY2024: 30.5MFY2025: 29.8M FY2017FY2019FY2021FY2023FY2025

Revenue by region

year to Dec 31, 2025
RevenueSharevs year before
United States 872.1M95.6% +13.1%
All other countries 39.9M4.4% +25.6%

10-K 0001609550-26-000016, segment and revenue notes (XBRL).

Income statement

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue16.4M28.6M50.6M82.0M115.4M233.4M407.9M624.8M802.8M912.0M
Cost of revenue3.9M6.0M10.1M13.6M17.6M33.3M66.1M96.6M123.0M133.2M
Gross profit12.5M22.5M40.5M68.4M97.8M200.1M341.7M528.2M679.8M778.8M
R&D7.1M6.2M7.4M12.8M26.1M37.4M68.6M116.5M114.1M103.2M
SG&A22.7M32.4M53.5M90.5M127.9M202.6M320.7M452.0M529.6M624.6M
Operating income-17.3M-16.0M-20.4M-34.9M-56.2M-39.9M-47.6M-40.3M36.1M51.0M
Interest expense1.3M1.8M3.3M2.1M2.1M2.1M1.7M022K137K
Pretax income-18.5M-17.5M-21.8M-33.2M-57.1M-42.0M-44.3M-19.9M58.5M65.7M
Income tax00040K115K72K613K1.2M4.9M-79.7M
Net income-18.5M-17.5M-21.8M-33.2M-57.2M-42.0M-44.9M-21.2M53.5M145.4M
EPS (diluted)-16.90-14.88-1.50-1.40-2.19-1.54-1.60-0.721.754.89
Diluted shares---23.8M26.1M27.3M28.1M29.3M30.5M29.8M
Depreciation & amortization103K285K393K495K840K1.2M1.9M2.8M6.5M14.0M
EBITDA-17.1M-15.7M-20.0M-34.4M-55.4M-38.6M-45.7M-37.4M42.6M64.9M
Gross margin76.2%78.9%80.1%83.4%84.7%85.7%83.8%84.5%84.7%85.4%
Operating margin-105.0%-56.0%-40.3%-42.5%-48.7%-17.1%-11.7%-6.4%4.5%5.6%
Net margin-112.8%-61.3%-43.1%-40.5%-49.6%-18.0%-11.0%-3.4%6.7%15.9%
Revenue growth-+73.9%+77.1%+62.2%+40.6%+102%+74.7%+53.2%+28.5%+13.6%
EPS growth---------+179%

Cash flow

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow-17.9M-15.8M-18.7M-32.8M-53.0M-20.1M11.6M24.7M130.2M117.0M
Capital spending306K412K250K2.7M2.5M4.7M9.1M23.6M39.1M38.5M
Free cash flow-18.3M-16.2M-18.9M-35.6M-55.5M-24.8M2.5M1.0M91.1M78.5M
Stock-based pay (added back)248K243K1.2M6.2M12.8M26.2M52.0M82.5M116.0M130.3M
Free cash flow after stock pay-18.5M-16.4M-20.2M-41.8M-68.3M-51.0M-49.5M-81.4M-24.9M-51.8M
Buybacks------000175.0M
Debt repaid----0024.5M00-
Investing cash flow-306K-7.6M-83.4M-43.6M86.6M29.1M-19.6M-294.8M-113.1M21.4M
Financing cash flow12.8M25.7M190.4M2.0M134.1M14.9M235.1M13.9M-52.4M-183.4M

Stock-based pay and leases

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Stock-based pay (expense)248K243K1.2M6.2M12.8M26.2M52.0M82.5M116.0M130.3M
Stock-based pay / revenue1.5%0.9%2.4%7.6%11.1%11.2%12.7%13.2%14.5%14.3%
Operating lease cost---1.0M1.0M1.1M1.5M2.2M3.0M3.4M
Operating lease cash paid---1.0M1.0M100K700K2.2M--
Right-of-use assets--0915K5.8M7.9M6.9M22.7M23.3M23.5M
Operating lease liabilities---828K5.9M9.1M8.9M24.8M31.8M32.2M

From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.

Sources

Every figure is from the company's XBRL filed with each 10-K and 10-Q (data.sec.gov). Hover a number for its line item; click it to open the filing.

Also

Company numbers: the figures the company reports beyond the statements. Peers: ten years, side by side.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/INSP/export.csv") into a cell.

Next:Peers in numbers
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.